2. Search Result
Search Result
Results for "

gastrointestinal dysfunction

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103108
    CJ033466

    		5-HT Receptor Metabolic Disease
    CJ033466 is a novel and selective 5-HT4 receptor partial agonist with an EC50 of 9 nM and has gastroprokinetic effect .
    CJ033466
  • HY-N0455B
    L-Arginine (L-glutamate)
    10+ Cited Publications

    (S)-(+)-Arginine (L-glutamate)

    		 Endogenous Metabolite NO Synthase Metabolic Disease
    L-Arginine L-glutamate ((S)-(+)-Arginine L-glutamate) is the nitrogen donor for synthesis of nitric oxide. L-Arginine L-glutamate can be used for upper gastrointestinal hypofunction or dysfunction like functional dyspepsia research .
    L-Arginine (L-glutamate)
  • HY-103146
    GR125487 sulfamate

    		5-HT Receptor Neurological Disease
    GR125487 sulfamate is an orally active and selective antagonist of 5-HT4R. GR125487 sulfamate effectively blocks the cognition enhancing effect. GR125487 sulfamate can be used to study memory disorders, gastrointestinal disorders, mood disorders and urinary tract dysfunction .
    GR125487 sulfamate
  • HY-N0455BR
    L-Arginine (L-glutamate) (Standard)

    (S)-(+)-Arginine (L-glutamate) (Standard)

    		 Endogenous Metabolite NO Synthase Metabolic Disease
    L-Arginine (L-glutamate) (Standard) is the analytical standard of L-Arginine (L-glutamate). This product is intended for research and analytical applications. L-Arginine L-glutamate ((S)-(+)-Arginine L-glutamate) is the nitrogen donor for synthesis of nitric oxide. L-Arginine L-glutamate can be used for upper gastrointestinal hypofunction or dysfunction like functional dyspepsia research[1].
    L-Arginine (L-glutamate) (Standard)
  • HY-159923
    BPRMU191

    		Opioid Receptor Neurological Disease
    BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation .
    BPRMU191